15 studies found for:    RARA
Show Display Options
Rank Status Study
1 Unknown  Effect of All-trans Retinoic Acid With Chemotherapy Based on Paclitaxel and Cisplatin As First-line Treatment of Patients With Advanced Non-small Cell Lung Cancer and Expression of RAR-alfa and RAR-beta as Response Biomarker
Condition: Non Small Cell Lung Cancer
Interventions: Drug: atRA;   Drug: Placebo
2 Unknown  Treatment Protocol for Relapsed Acute Promyelocytic Leukemia (APL) With Arsenic
Conditions: Relapsed Acute Promyelocytic Leukemia;   Refractory Acute Promyelocytic Leukemia
Interventions: Drug: Arsenic trioxide;   Drug: Trisenox
3 Recruiting Treatment of Relapsed Promyelocytic Leukemia With Arsenic Trioxide (ATO)
Condition: Acute Promyelocytic Leukemia
Interventions: Drug: Arsenic Trioxide;   Procedure: Autologous Transplantation;   Procedure: Allogenic Transplantation;   Drug: ATRA
4 Completed Biomarkers in Tissue Samples From Patients With Acute Promyelocytic Leukemia
Condition: Leukemia
Interventions: Genetic: protein expression analysis;   Genetic: western blotting;   Other: flow cytometry;   Other: laboratory biomarker analysis
5 Recruiting Acute Promyelocytic Leukemia 2006 (APL)
Condition: Leukemia, Promyelocytic, Acute
Interventions: Procedure: Arsenic trioxide;   Procedure: ATRA
6 Completed Treatment of Acute Promyelocytic Leukemia With All-Trans Retinoic Acid (ATRA) and Idarubicin (AIDA)
Condition: Acute Promyelocytic Leukemia
Intervention: Drug: AIDA
7 Unknown  AIDA 2000 Guidelines
Condition: Acute Promyelocytic Leukemia
Intervention: Drug: all-trans retinoic acid (ATRA)
8 Unknown  Study of NRX 195183 Therapy for Patients With Relapsed or Refractory Acute Promyelocytic Leukemia
Condition: Acute Promyelocytic Leukemia
Intervention: Drug: NRX 195183 Soft Gelatin Capsule
9 Recruiting Study of Dasatinib and All-Trans Retinoic Acid for Relapsed/Refractory and/or Elderly Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome
Conditions: Acute Myelogenous Leukemia;   Myelodysplastic Syndrome
Interventions: Drug: dasatinib (SPRYCEL);   Drug: all trans retinoic acid (VESANOID)
10 Completed Arsenic Trioxide in Treating Patients With Refractory or Recurrent Acute Promyelocytic Leukemia
Condition: Leukemia
Intervention: Drug: arsenic trioxide
11 Active, not recruiting Phase III Trial in Acute Promyelocytic Leukemia Patients
Condition: Leukemia
Interventions: Drug: arsenic trioxide;   Drug: idarubicin;   Drug: mercaptopurine;   Drug: methotrexate;   Drug: all-trans retinoic acid;   Drug: all-trans retinoic acid (ATRA)
12 Recruiting Necrotizing Enterocolitis (NEC) & Platelet-Activating Factor (PAF)-Stimulated Protein Translation in Premature Infants
Condition: Necrotizing Enterocolitis (NEC)
Intervention:
13 Recruiting Treatment Study for Children and Adolescents With Acute Promyelocitic Leukemia
Condition: Acute Promyelocytic Leukemia
Interventions: Drug: ATRA;   Drug: ATRA + IDA
14 Active, not recruiting Targeted High Throughput Sequencing in the Diagnosis of Pediatric Acute Leukemia
Condition: Pediatric Acute Leukemia
Intervention: Other: blood draw
15 Completed Combination Chemotherapy in Treating Patients With Acute Promyelocytic Leukemia
Condition: Leukemia
Interventions: Drug: arsenic trioxide;   Drug: cytarabine;   Drug: daunorubicin hydrochloride;   Drug: mercaptopurine;   Drug: methotrexate;   Drug: tretinoin

Indicates status has not been verified in more than two years